Company Profile
CEO
Mr. Robert A. Bradway(Chairman & CEO)
Sector
Healthcare
Industry
Drug Manufacturers - General
Employees
31.5K
Beta
0.42
Forward P/E
14.8
52W High
$391.29
52W Low
$267.83
Profit Margin
21.0%
Operating Margin
33.8%
Return on Equity
101.3%
Revenue Growth
5.8%
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic a...
Valuation
Market Cap$186.59B
P/E (TTM)24.04
P/S (TTM)5.41
EV/EBITDA15.33
Cash Flow
FCF Yield+3.2%
SBC Adj. FCF Yield+3.0%
SBC Impact5.1%
Margins & Growth
Profit Margin21.1%
Operating Margin30.9%
Revenue YoY5.8%
Earnings YoY5.1%
Balance
Cash$12.04B
Debt$57.32B
Net Cash$-45.28B
Dividend
Dividend Yield2.92%
Payout Ratio74.9%
Quarterly Payout$1.36B